Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | USP8 | P40818 | 2/20 | 0.34 |
| ▸ | USP7 | Q93009 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31511514 | 1.00 | CSNK1A1 (0.41) | CSNK1A1CLK4KDM4EALDH1A1POLB | |
| SCHEMBL11032347 | 0.85 | PIK3CD (0.43) | CSNK1A1CLK4KDM4EALDH1A1POLB | |
| SCHEMBL24146632 | 0.83 | CSNK1A1 (0.41) | CSNK1A1CLK4KDM4EALDH1A1POLB | |
| SCHEMBL376394 | 0.78 | ALDH1A1 (0.42) | CSNK1A1CLK4KDM4EALDH1A1POLB | |
| SCHEMBL29420836 | 0.78 | ALDH1A1 (0.42) | CSNK1A1CLK4KDM4EALDH1A1POLB | |
| SCHEMBL25503292 | 0.77 | KDM4E (0.41) | CSNK1A1CLK4KDM4EALDH1A1POLB | |
| SCHEMBL22835804 | 0.76 | CDK2 (0.33) | CDK2SCN2A | |
| SCHEMBL15142766 | 0.75 | PIK3CD (0.40) | CSNK1A1CLK4KDM4EALDH1A1POLB | |
| SCHEMBL8139272 | 0.75 | KDM4E (0.40) | CSNK1A1CLK4KDM4EALDH1A1POLB | |
| SCHEMBL7781784 | 0.74 | USP8 (0.40) | CSNK1A1CLK4PIK3CDUSP8ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115279771-B | MAP4K1 inhibitors | 缆图药品公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12209098-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| US-20240336630-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2024-10-10 | — | — | US | disclosed |
| US-12042495-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-23 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| CN-117940406-A | MAP4K1 inhibitors | 缆图药品公司 | 2024-04-26 | — | — | CN | disclosed |
| US-11952386-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2024-04-09 | — | — | US | disclosed |
| EP-4313308-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3865484-B1 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H LUNDBECK AS (DK) | 2023-11-08 | — | — | EP | disclosed |
| EP-2197874-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009103966-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009103966-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| US-7163939-B2 | Macrocyclic kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1682555-A1 | MACROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050215556-A1 | Macrocyclic kinase inhibitors | ABBVIE INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005047294-A1 | MACROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050096324-A1 | Macrocyclic kinase inhibitors | ABBOTT LABORATORIES | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096324-A1 | Macrocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K7 | CSNK1A1 52/4885CLK4 597/4885KDM4E 1650/4885 |
| US-20240336630-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | CSNK1A1 71/4885CLK4 186/4885KDM4E 834/4885 |
| US-11952386-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN7 | CSNK1A1 148/4885CLK4 3159/4885KDM4E 937/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | CSNK1A1 471/4885CLK4 3090/4885KDM4E 1134/4885 |
| US-20050215556-A1 | Macrocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K7 | CSNK1A1 52/4885CLK4 597/4885KDM4E 1650/4885 |
| US-12209098-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN7 | CSNK1A1 148/4885CLK4 3159/4885KDM4E 937/4885 |
| US-12042495-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | CSNK1A1 78/4885CLK4 189/4885KDM4E 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.